Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma;Perspektiven der molekularen diagnostik dargestellt am beispiel des harnblasenkarzinoms

Urologe - Ausgabe A

Volumn 42, Issue 5, 2003, Pages 650-659

  Grimm, M O ^a   Burchardt, M ^a   Schulz, W A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bladder cancer; Chemoresistance; Predisposition; Prognosis; Signal transduction inhibitors

Indexed keywords

CYTOSTATIC AGENT; PROTEIN P53;

BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CYSTECTOMY; DISEASE COURSE; DISEASE PREDISPOSITION; GENE EXPRESSION PROFILING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; PHYSICIAN; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0038509103     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0349-9     Document Type: Review

References (60)

1. Aben KKH, Kiemeney LALM (1999) Epidemiology of bladder cancer. European Urology 36:1-13
2. Filiadis I, Hrouda D (2000) Genetic factors in chemically-induced transitional cell bladder cancer. BJU Int 86:794-801
3. Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutation Research 506:65-77
4. Golka K, Prior V, Blaszkewicz M et al. (1996) Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health 22:332-338
5. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM (1997) Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloro-ethene. Arch Toxicol 71:596-599
6. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159-1164
7. Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I (1994) Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 54:4103-4111
8. Engel LS, Taioli E, Pfeiffer R et al. (2002) Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 156:95-109
9. Smith MT (1999) Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA 96:7624-7626
10. Moran JL, Siegel D, Ross D (1999) A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H: quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 96:8150-8155
11. Eickelmann P, Schulz WA, Rohde D, Schmitz-Drager B, Sies H (1994) Loss of heterozygosity at the NAD(P)H: quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe Seyler 375:439-445
12. Schulz WA, Krummeck A, Rosinger I et al. (1997) Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics 7:235-239
13. Clasen S, Schulz WA, Gerharz CD, Grimm MO, Christoph F, Schmitz-Drager BJ (1998) Frequent and heterogeneous expression of cyclin-dependent kinase in hibitor WAF1/p21 protein and mRNA in urothelial carcinoma. Br J Cancer 77:515-521
14. Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA (2000) DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 80:1513-1522
15. Franke KH, Miklosi M, Goebell P et al. (2000) Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. Urology 56:689-695
16. Schmitz-Drager BJ, Kushima M, Goebell P et al. (1997) p53 and MDM 2 in the development and progression of bladder cancer. Eur Urol 32:487-493
17. Knowles MA (2001) What we could do now: molecular pathology of bladder cancer. Mol Pathol 54:215-221
18. Cote RJ, Dunn MD, Chatterjee SJ et al. (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58:1090-1094
19. Esrig D, Elmajian D, Groshen S et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264
20. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y (2000) p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 38:691-699
21. Lipponen P, Aaltomaa S, Eskelinen M, Ala-Opas M, Kosma VM (1998) Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 34:237-243
22. Stein JP Ginsberg DA, Grossfeld GD et al. (1998) Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90:1072-1079
23. Cordon-Cardo C, Zhang ZF, Dalbagni G et al. (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57:1217-1221
24. Lianes P, Charytonowicz E, Cordon-Cardo C et al. (1998) Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res 4:1267-1271
25. Marki ID, Jones PA (1998) Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 58:5348-5353
26. Dyrskjot L, Thykjaer T, Kruhoffer M et al. (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Gen 33:90-96
27. Duyk GM (2002) Sharper tools and simpler methods. Nat Gen 32 [Suppl]:465-468
28. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J (1997) Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157:1054-1058
29. Yang CR, Ou YC, Kuo JH et al. (1997) Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response. Cancer Lett 119:157-162
30. Ishikawa T, Wright CD, Ishizuka H (1994) GS-X pump is functionally overexpressed in cis-diamminedichloro-platinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269:29085-29093
31. Bahnson RR, Bedch M, Emstoff MS, Sandlow J, Cohen MB, Williams RD (1994) Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 152:2272-2275
32. Kotoh S, Naito S, Sakamoto N, Goto K, Kumazawa J (1994) Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 152:1267-1270
33. Satoh M, Cherian MG, Imura N, Shimizu H (1994) Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 54:5255-5257
34. Yu DS, Chang SY, Ma CP (1997) The correlation of membranous glycoprotein-gp-170, cytoplasmic glutathione and glucose-6-phosphate dehydrogenase levels with multidrug resistance in transitional cell carcinoma cell lines of the urinary tract. J Urol 157:727-731
35. Pu YS, Tsai TC, Cheng AL, Tsai CY, Tseng NF, Su IJ, Hsieh CY, Lai MK (1996) Expression of MDR-1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J Urol 156:271-275
36. Guo H, Lu G, Xiong X, Dong J, Liu S (1997) Establishment of doxorubicin-resistant human bladder cancer cell line (BUI-87/ADMR) and its mechanism of multidrug resistance. Chin Med J (Engl) 110:167-172
37. Kakehi Y, Ozdemir E, Habuchi T, Yamabe H, Hashimura T, Katsura Y, Yoshida O (1998) Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 89:214-220
38. Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K (2000) Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 91:416-423
39. Sarkis AS, Bajorin DF, Reuter VE et al. (1995) Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13:1384-1390
40. Sengelov L, Horn T, Steven K (1997) p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 123:565-570
41. Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF, Moore MJ (1998) The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559-565
42. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S (1999) Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J Urol 162:2176-2181
43. Tiguert R, Lessard A, So A, Fradet Y (2002) Prognostic markers in muscle invasive bladder cancer. World J Urol 20:190-195
44. Skinner DG, Daniels JR, Russell CA et al. (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459-464
45. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG (1997) p53 and treatment of bladder cancer. Nature 385:123-125
46. Los G, Yang F, Samimi G et al. (2002) Using mRNA expression profiling to determine anticancer drug efficacy. Cytometry 47:66-71
47. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE (1996) C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 155:321-326
48. Gandour-Edwards R, Lara PN, Folkins AK et al. (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009-1015
49. Meye A, Fiedler U, Kunert K et al. (2001) Growth inhibitory effects of ZD1839 ('Iressa') on human bladder cancer cell lines. Proc Am Assoc Cancer Res 42:805
50. Perrotte P, Matsumoto T, Inoue K et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265
51. Inoue K, Slaton JW, Perrotte P et al. (2000) Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6:4874-4884
52. Baselga J, Pfister D, Cooper MR et al. (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914
53. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 [Suppl]:1-13
54. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28:13-19
55. Fornier M, Esteva FJ, Seidman AD (2000) Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin Oncol 27:38-45
56. Sauter G, Haley J, Chew K et al. (1994) Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 57:508-514
57. Sako Y, Minoghchi S, Yanagida T (2000) Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol 2:168-172
58. Worthylake R, Opresko LK, Wiley HS (1999) ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274:8865-8874
59. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
60. Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E (2001) A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61:6227-6233